author-photo

Allan R. Tenorio

Research Triangle Park

11

Papers

223

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study.

2020 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (65)
Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial

2019 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (34)
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min

2019 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

2019 Journal of Acquired Immune Deficiency Syndromes
Show All
- Source
- Cite
- Save
Citations (49)
Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (11)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (10)
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (12)
The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects

2018 Pharmacology Research & Perspectives
Show All
- Source
- Cite
- Save
Citations (11)